Panel: In Abandoning Product, Appellant Lost Standing In Patent Appeal
WASHINGTON, D.C. — Momenta Pharmaceuticals Inc. forfeited any legally protected interest in the validity of a Bristol-Myers Squibb Co. (BMS) patent when it abandoned development of a proposed biosimilar drug, the...To view the full article, register now.
Already a subscriber? Click here to view full article